GlassScriptPhysician profile
Omar Khayyat
NPI 1649711862
$1,454.34
in general payments reported to CMS, 2019-2025
16 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.50 · 2021: $22.49 · 2022: $218 · 2023: $41.31 · 2024: $507 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163 · Travel and Lodging: $8.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.88 |
| Travel and Lodging | $8.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $411.94 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $255.31 | 2024-2025 | Airsupra, Fasenra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $217.60 | 2022 | |
| Novo Nordisk INC | $121.69 | 2024-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $119.27 | 2024-2025 | Gvoke Hypopen |
| Shield Therapeutics INC | $57.97 | 2025 | |
| Amgen INC. | $56.16 | 2024-2025 | Otezla, Repatha, Repatha |
| Corcept Therapeutics | $44.60 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $23.52 | 2025 | Nucala |
| Genentech USA, INC. | $22.99 | 2019 | |
| Abbott Laboratories | $22.80 | 2025 | Mitraclip |
| Pfizer INC. | $22.17 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $21.87 | 2025 | Zoryve |
| Gilead Sciences, INC. | $20.32 | 2024 | |
| Merck Sharp & Dohme LLC | $19.51 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $16.62 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Khayyat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.